- Home
- CNTB vs MOLN Comparison
CNTB vs MOLN Comparison
Compare CNTB & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNTB | MOLN |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 144.0M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNTB | MOLN |
|---|---|---|
| Price | $2.59 | $4.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $8.67 | $8.38 |
| AVG Volume (30 Days) | ★ 441.5K | 2.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $64,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $3.36 |
| 52 Week High | $3.82 | $5.36 |
Technical Indicators
Market Signals| Indicator | CNTB | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 51.67 |
| Support Level | $2.50 | $4.04 |
| Resistance Level | $2.97 | $4.50 |
| Average True Range (ATR) | 0.27 | 0.13 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 5.00 | 72.47 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.